Alexza Trademarks Sample Clauses

Alexza Trademarks. Trademark Country Filing Date Application Number Registration Date Registration Number [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXHIBIT 1.36 Structure of Loxapine Nomenclature (Loxapine) • International Nonproprietary Name: Loxapine Free Base • Chemical name: 2-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]-oxazepine • Synonym: Oxilapine • Commercial name: Loxitane • CAS Number: 1977.10-2 Structure (Loxapine) • Molecular Formula: C18H18ClN3O • Relative Molecular Mass: 327.81 • Structural Formula [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXHIBIT 1.40 FDA MANDATED STUDIES [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ORANGE BOOK PATENTS I Patent Number Grant Date Expiration Date Title [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 8/18/2024 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 10/23/2026 [ * ] Exhibit 1.73 ORANGE BOOK PATENTS II Patent Number Grant Date Expiration Date Title [ * ] [ * ] 5/22/2022 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 5/20/2022 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] [ * ] 10/26/2021 [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXHIBIT 6.7 SUPPLIERS Supplier Location Product Description [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. EXHIBIT 9.5(A) FORM OF PRESS RELEASE Teva and Alexza Announce Teva’s License to Market Adasuve® in the U.S. Adasuve® ...
Sample 1
AutoNDA by SimpleDocs
Alexza Trademarks. Trademark Country Filing Date Application Number Registration Date Registration Number [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 1.30 Structure of Loxapine Nomenclature (Loxapine) • International Nonproprietary Name: Loxapine Free Base • Chemical name: 2-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]-oxazepine • Synonym: Oxilapine • Commercial name: Loxitane • CAS Number: 1977.10-2 Structure (Loxapine,) • Molecular Formula: C18H 18ClN3O • Relative Molecular Mass: 327.81 • Structural Formula [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Alexza Trademarks. Trademark Country Filing Date Application Number Registration Date Registration Number ADASUVE United States 06/04/2009 77/752,342 ADASUVE Canada 11/25/2009 1460520 ALEXZA United States 05/25/2001 76/262,728 08/22/2006 3133370 ALEXZA Canada 04/03/2007 1341955 03/12/2008 000000 XXXXXX XXXXXXXXXXXXXXX Xxxxxx Xxxxxx 05/25/2001 76/262,729 07/12/2005 2967469 STACCATO United States 06/28/2002 78/139,872 08/08/2006 3127490 STACCATO Canada 12/18/2002 1162836 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 1.73 Structure of Loxapine Nomenclature (Loxapine) • International Nonproprietary Name: Loxapine Free Base • Chemical name: 2-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]-oxazepine • Synonym: Oxilapine • Commercial name: Loxitane • CAS Number: 1977.10-2 Structure (Loxapine) • Molecular Formula: C18H18ClN3O • Relative Molecular Mass: 327.81 • Structural Formula [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Supply Agreement {Please see Exhibit 10.56 to the 10-K} [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 8.5(a) Form of Press Release(s) CONTACT: Xxxxxx X. Xxxxxx Vice-President, Investor Relations and Corporate Communications (000) 000-0000 BIOVAIL ENTERS INTO LICENSE AND COLLABORATION AGREEMENT WITH ALEXZA FOR AZ-004 NDA Filed by Alexza in Dec. 2009; Undergoing FDA Review for Treatment of Agitation; Targets Unmet Medical Need; Further Builds Specialty CNS Pipeline TORONTO, Canada, February 10, 2010 – Biovail Corporation (NYSE, TSX: BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc. BLS has acquired the U.S. and Canadian rights to commercialize AZ-004 – a novel formulation of loxapine administered via deep lung inhalation using Alexza’s proprietary Staccato® device. AZ-004 is initially targeted for the rapid treatment of agitatio...
Sample 1
Alexza Trademarks 
Sample 1

Related to Alexza Trademarks

  • Product Trademarks BMS shall be solely responsible for the selection (including the creation, searching and clearing), registration, maintenance, policing and enforcement of all trademarks developed for use in connection with the marketing, sale or distribution of Products in the Field in the Territory (the “Product Marks”). BMS shall own all Product Marks, and all trademark registrations for said marks.

  • Trademarks; Tradenames As soon as practicable after the Closing Date, Seller shall eliminate the use of all of the trademarks, tradenames, service marks and service names used in the Business, in any of their forms or spellings, on all advertising, stationery, business cards, checks, purchase orders and acknowledgments, customer agreements and other contracts and business documents. Seller shall grant Buyer the right to use the ClearStory name, as described in the Trademark License Agreement at Exhibit B.

  • Patents, Trademarks There are no material patents, patent rights, trademarks, service marks, trade names, copyrights, licenses or other intellectual property rights with respect to the Leased Property that are necessary for the operation of the Leased Property by the Lessee, except to the extent that the Lessee has rights in respect thereof without material payment of royalties or other material licensing payments, which rights may be freely leased, licensed or otherwise provided to Lessor or any successor owner, lessee, user or operator of the Leased Property pursuant to the Operative Documents.

  • Trademarks All tradenames, trademarks, servicemarks, logos, copyrights, goodwill, books and records and all other general intangibles relating to or used in connection with the operation of the Property;

  • Trademarks, Patents Borrower, as of the date hereof, possesses all necessary trademarks, trade names, copyrights, patents, patent rights, and licenses to conduct its business as now operated, without any known conflict with the valid trademarks, trade names, copyrights, patents and license rights of others.

  • Trademarks and Service Marks In the event the Administrative Agent forecloses on its security interest in the License Agreements and transfers the License Agreements to a Person who does not meet the Successor Manager Requirements, then Sprint PCS shall have the right to terminate the License Agreements and cause the Administrative Agent to release its security interest in the License Agreements immediately prior to such transfer.

  • Patents, Trademarks, Etc Each Borrower and their Subsidiaries owns, possesses, or has the right to use all necessary Patents, licenses, Trademarks, Copyrights, permits and franchises to own its properties and to conduct its business as now conducted, without known conflict with the rights of any other Person. Any and all obligations to pay royalties or other charges with respect to such properties and assets are properly reflected on the financial statements described in Section 4.1.11 (Financial Condition).

  • Trademark Use (a) Reseller acknowledges that the Vendor Trademarks are trademarks owned solely and exclusively by Vendor, and agrees to use the Vendor Trademarks only in the form and manner and with appropriate legends as prescribed by Vendor. Reseller agrees not to use any other trademark or service mark xx connection with any of the Vendor Trademarks without prior written approval of Vendor. All use of Vendor Trademarks shall inure to the benefit of Vendor.

  • Patents, Trademarks, Copyrights and Licenses All patents, patent applications, trademarks, trademark applications, service marks, service xxxx applications, copyrights, copyright applications, design rights, tradenames, assumed names, trade secrets and licenses owned or utilized by any Borrower are set forth on Schedule 5.9, are valid and have been duly registered or filed with all appropriate Governmental Bodies and constitute all of the intellectual property rights which are necessary for the operation of its business; there is no objection to or pending challenge to the validity of any such patent, trademark, copyright, design rights, tradename, trade secret or license and no Borrower is aware of any grounds for any challenge, except as set forth in Schedule 5.9 hereto. Each patent, patent application, patent license, trademark, trademark application, trademark license, service xxxx, service xxxx application, service xxxx license, design rights, copyright, copyright application and copyright license owned or held by any Borrower and all trade secrets used by any Borrower consist of original material or property developed by such Borrower or was lawfully acquired by such Borrower from the proper and lawful owner thereof. Each of such items has been maintained so as to preserve the value thereof from the date of creation or acquisition thereof. With respect to all software used by any Borrower, such Borrower is in possession of all source and object codes related to each piece of software or is the beneficiary of a source code escrow agreement, each such source code escrow agreement being listed on Schedule 5.9 hereto.

  • Trademarks, Etc Except to the extent required by applicable law, no Party shall use any other Party's names, logos, trademarks or service marks, whether registered or unregistered, without the prior consent of such Party.

Time is Money Join Law Insider Premium to draft better contracts faster.